Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
1.58(c) 1.68(c) 1.58(c) 1.37(c) 1.37 Last
9 855 063 12 735 137 5 324 596 3 553 023 2 828 739 Volume
0.00% +6.33% -5.95% -13.29% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -152 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,40x
Yield 2021 -
Sales 2022 32,1 M - -
Net income 2022 -132 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,89x
Yield 2022 -
Capitalization 218 M 218 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 6,80x
Nbr of Employees 176
Free-Float 98,5%
More Financials
Company
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 02:40pmPresentation
More about the company
Ratings of Spectrum Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about SPECTRUM PHARMACEUTICALS, INC.
08:00aSpectrum Pharmaceuticals Submits New Drug Application for Poziotinib to US Food and Dru..
MT
07:04aSpectrum Pharmaceuticals Submits New Drug Application for Poziotinib
BU
12/03SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
12/01Spectrum Pharmaceuticals CEO Agrees to Retire, COO Named Successor From Dec. 31
MT
12/01Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
BU
12/01Spectrum Pharmaceuticals, Inc. Announces Appointment of Tom Riga as President and CEO, ..
CI
12/01Spectrum Pharmaceuticals, Inc. Announces Changes to Board of Directors
CI
11/30Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summi..
BU
11/11Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
BU
11/10Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Upd..
PU
11/10Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/10SPECTRUM PHARMA : Q3 Earnings Snapshot
AQ
11/10Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Upd..
BU
11/03Spectrum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Provide Cor..
BU
11/03SHAREHOLDER ALERT : Robbins LLP Investigates Spectrum Pharmaceuticals, Inc. (SPPI) for Mis..
BU
More news
News in other languages on SPECTRUM PHARMACEUTICALS, INC.
08:00aSpectrum Pharmaceuticals soumet une demande de nouveau médicament pour le poziotinib à ..
12/01Le PDG de Spectrum Pharmaceuticals accepte de prendre sa retraite, le directeur de l'ex..
10/07Le combo Poziotinib de Spectrum Pharma présente des données "prometteuses" lors d'un es..
08/06Spectrum Pharmaceuticals déclare que la FDA a rejeté la demande d'homologation de son m..
07/14Spectrum Pharmaceuticals dépose une demande de placement de titres mixtes pour un monta..
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Chart SPECTRUM PHARMACEUTICALS, INC.
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,37 $
Average target price 5,75 $
Spread / Average Target 320%
EPS Revisions
Managers and Directors
Joseph W. Turgeon President, Chief Executive Officer & Director
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
William L. Ashton Chairman
Francois Lebel Chief Medical Officer
Lyndah K. Dreiling Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SPECTRUM PHARMACEUTICALS, INC.-50.73%218
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298